AnaBios Acquires Cell Systems
April 4, 2023
AnaBios Corporation has acquired Cell Systems, a Kirkland, Washington supplier of human primary cells and cell culture media, to expand its human tissue and cell portfolio and accelerate translational drug discovery. Financing for the transaction was provided by AnaBios' existing investors, including Ampersand Capital Partners; financial terms were not disclosed.
- Buyers
- AnaBios Corporation, Ampersand Capital Partners
- Targets
- Cell Systems
- Platforms
- AnaBios Corporation
- Industry
- Biotechnology
- Location
- Washington, United States
- Transaction Type
- Addon
Explore More
Related Acquisitions
-
CellBio Scientific Acquires BioChain
May 1, 2025
Biotechnology
CellBio Scientific, a provider of life science tools and research services, has acquired BioChain, a biospecimen collection, preparation, and analysis company based in Newark, California. The acquisition expands CellBio Scientific's capabilities in spatial genomics and biospecimen workflows, consolidating BioChain with System Biosciences and Acepix Biosciences to create a broader translational research platform.
-
Ampersand Capital Partners Acquires Biologos LLC
March 19, 2024
Biotechnology
Ampersand Capital Partners, a healthcare-focused private equity firm, has acquired Biologos LLC, a Glendale Heights, Illinois-based manufacturer of custom and standard cell culture media, reagents, buffers, enzymes, and sera. Ampersand will invest to expand Biologos' capabilities, product offerings, and geographic reach, and has appointed Frank Witney as Chairman with two Ampersand principals joining the board.
-
Discovery Life Sciences Acquires AllCells
July 12, 2022
Biotechnology
Discovery Life Sciences has acquired AllCells to create an integrated, end-to-end provider of clinical-grade and RUO primary cell products and analytic services for the cell and gene therapy (CGT) continuum. The combined business — operating as AllCells, a Discovery Life Sciences Company and led by AllCells CEO Danny Zheng — aims to expand GMP-compliant starting materials, donor programs and multi‑omic characterization to accelerate CGT discovery through commercialization.
-
Ampersand Capital Partners Invests in AnaBios Corporation
June 7, 2022
Healthcare Services
Ampersand Capital Partners has made a growth equity investment in San Diego-based AnaBios Corporation, a preclinical contract research organization specializing in translational research using human tissues. The investment will be used to expand AnaBios’s capabilities, therapeutic area coverage and global reach to support more successful drug discovery and development programs.
-
Axion BioSystems Acquires CytoSMART Technologies
March 21, 2022
Medical Devices
Axion BioSystems has acquired Netherlands-based CytoSMART Technologies, a developer of kinetic live-cell imaging systems and AI-powered image analysis tools. The acquisition expands Axion's product portfolio and capabilities in live-cell imaging to support research in stem cell biology, immuno-oncology, cell-based therapies, and drug discovery.
-
Bruker Corporation Acquires Canopy Biosciences, LLC
September 11, 2020
Biotechnology
Bruker Corporation has acquired Canopy Biosciences, LLC to strengthen its targeted multi-omics and high-plex biomarker imaging capabilities, adding Canopy's ChipCytometry platform and multi-omics services. Financial terms were not disclosed; Ampersand Capital Partners was identified as Canopy's lead investor.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.